380 related articles for article (PubMed ID: 34098569)
1. Evaluation of Low-density Lipoprotein Cholesterol Target Attainment Rates According to the 2016 and 2019 European Society of Cardiology/European Atherosclerosis Society Dyslipidemia Guidelines for Secondary Prevention in Patients with Acute Myocardial Infarction.
Şimşek B; İnan D; Çınar T; Cagdas-Yumurtaş A; Ozan-Tanık V; Zeren G; İlker-Avcı İ; Yücel-Karabay C; Güngör B; Tokgozoğlu L
Rev Invest Clin; 2021 Nov; 73(3):371-378. PubMed ID: 34098569
[TBL] [Abstract][Full Text] [Related]
2. How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic.
Barkas F; Milionis H; Kostapanos MS; Mikhailidis DP; Elisaf M; Liberopoulos E
Curr Med Res Opin; 2015 Feb; 31(2):221-8. PubMed ID: 25418708
[TBL] [Abstract][Full Text] [Related]
3. Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study.
Allahyari A; Jernberg T; Hagström E; Leosdottir M; Lundman P; Ueda P
Eur Heart J; 2020 Oct; 41(40):3900-3909. PubMed ID: 32072178
[TBL] [Abstract][Full Text] [Related]
4. Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice.
Arca M; Ansell D; Averna M; Fanelli F; Gorcyca K; Iorga ŞR; Maggioni AP; Paizis G; Tomic R; Catapano AL
Atherosclerosis; 2018 Apr; 271():120-127. PubMed ID: 29499359
[TBL] [Abstract][Full Text] [Related]
5. Low-density lipoprotein-cholesterol target attainment according to the 2011 and 2016 ESC/EAS dyslipidaemia guidelines in patients with a recent myocardial infarction: nationwide cohort study, 2013-17.
Allahyari A; Jernberg T; Lautsch D; Lundman P; Hagström E; Schubert J; Boggs R; Salomonsson S; Ueda P
Eur Heart J Qual Care Clin Outcomes; 2021 Jan; 7(1):59-67. PubMed ID: 32142112
[TBL] [Abstract][Full Text] [Related]
6. Achievement of LDL-C Targets Defined by ESC/EAS (2011) Guidelines in Risk-Stratified Korean Patients with Dyslipidemia Receiving Lipid-Modifying Treatments.
Yang YS; Lee SY; Kim JS; Choi KM; Lee KW; Lee SC; Cho JR; Oh SJ; Kim JH; Choi SH
Endocrinol Metab (Seoul); 2020 Jun; 35(2):367-376. PubMed ID: 32615721
[TBL] [Abstract][Full Text] [Related]
7. Lipid Lowering Treatment and Eligibility for PCSK9 Inhibition in Post-Myocardial Infarction Patients in Italy: Insights from Two Contemporary Nationwide Registries.
Colivicchi F; Massimo Gulizia M; Arca M; Luigi Temporelli P; Gonzini L; Venturelli V; Morici N; Indolfi C; Gabrielli D; De Luca L
Cardiovasc Ther; 2020; 2020():3856242. PubMed ID: 31969932
[TBL] [Abstract][Full Text] [Related]
8. The DA VINCI study: is Ireland achieving ESC/EAS guideline-directed LDL-C goals?
Offiah G; O'Connor C; Kennedy C; Gallagher J; O'Connor P; McAdam B; Ray KK; Schoonen M; Maher V
Ir J Med Sci; 2023 Jun; 192(3):1077-1084. PubMed ID: 35776266
[TBL] [Abstract][Full Text] [Related]
9. Current lipid lowering treatment and attainment of LDL targets recommended by ESC/EAS guidelines in very high-risk patients with established atherosclerotic cardiovascular disease: Insights from the START registry.
De Luca L; Arca M; Temporelli PL; Meessen J; Riccio C; Bonomo P; Colavita AR; Gabrielli D; Gulizia MM; Colivicchi F;
Int J Cardiol; 2020 Oct; 316():229-235. PubMed ID: 32470532
[TBL] [Abstract][Full Text] [Related]
10. Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics.
Morieri ML; Avogaro A; Fadini GP;
Cardiovasc Diabetol; 2020 Nov; 19(1):190. PubMed ID: 33172454
[TBL] [Abstract][Full Text] [Related]
11. How Did the Updated 2019 European Society of Cardiology/European Atherosclerosis Society Risk Categorization for Patients with Diabetes Affect the Risk Perception and Lipid Goals? A Simulated Analysis of Real-life Data from EPHESUS Study.
Başaran Ö; Doğan V; Mert KU; Özlek B; Özlek E; Çelik O; Çil C; Özdemir İH; Rencüzoğulları İ; Özpamuk Karadeniz F; Tekinalp M; Aşkın L; Demirelli S; Gencer E; Bekar L; Aktaş M; Resulzade MM; Kalçık M; Aksan G; Çinier G; Halil Akay K; Pekel N; Mert GÖ; Şenol U; Demir V; İnci S; Derviş E; Biteker M; Kayıkçıoğlu M
Anatol J Cardiol; 2023 Feb; 27(2):78-87. PubMed ID: 36747449
[TBL] [Abstract][Full Text] [Related]
12. Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients.
Gitt AK; Lautsch D; Ferrieres J; Kastelein J; Drexel H; Horack M; Brudi P; Vanneste B; Bramlage P; Chazelle F; Sazonov V; Ambegaonkar B
Atherosclerosis; 2016 Dec; 255():200-209. PubMed ID: 27667299
[TBL] [Abstract][Full Text] [Related]
13. An estimation of the consequences of reinforcing the 2016 and 2019 European Society of Cardiology/European Atherosclerosis Society guidelines on current lipid-lowering treatment in patients with type 2 diabetes in tertiary care-a SwissDiab study.
Singeisen H; Renström F; Laimer M; Lehmann R; Bilz S; Brändle M
Eur J Prev Cardiol; 2023 Oct; 30(14):1473-1481. PubMed ID: 37226890
[TBL] [Abstract][Full Text] [Related]
14. ESC/EAS guidelines for the detection, prevention, and treatment of individuals at risk of a first myocardial infarction: effect of 5 years of updates and the new SCORE2.
Sulman D; Zeitouni M; Silvain J; Kerneis M; Guedeney P; Barthélémy O; Brugier D; Sabouret P; Lattuca B; Mertens E; Posson J; Procopi N; Salloum T; Collet JP; Montalescot G
Eur Heart J Cardiovasc Pharmacother; 2022 Sep; 8(6):633-643. PubMed ID: 35381063
[TBL] [Abstract][Full Text] [Related]
15. Unused potential of lipid-lowering therapy in very high-risk patients with atherosclerotic cardiovascular disease. A retrospective data analysis.
Pohl SB; Engelbertz C; Reinecke H; Malyar NM; Meyborg M; Brix TJ; Varghese J; Gebauer K
Nutr Metab Cardiovasc Dis; 2024 Jul; 34(7):1670-1680. PubMed ID: 38664125
[TBL] [Abstract][Full Text] [Related]
16. Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease.
Chan J; Rajalingam T; Fossella J; Zhou H; Eisenberg N; Roche-Nagle G
Ann Vasc Surg; 2020 Nov; 69():197-205. PubMed ID: 32554202
[TBL] [Abstract][Full Text] [Related]
17. Dyslipidemia treatment and attainment of LDL-cholesterol treatment goals in patients participating in the Managed Care for Acute Myocardial Infarction Survivors program.
Nowowiejska-Wiewióra A; Wita K; Mędrala Z; Tomkiewicz-Pająk L; Bujak K; Mizia-Stec K; Brzychczy P; Gąsior M; Gąsior Z; Kulbat A; Kalarus Z; Wojakowski W; Trzeciak P; Witkowski A; Banach M; Legutko J
Kardiol Pol; 2023; 81(4):359-365. PubMed ID: 36871294
[TBL] [Abstract][Full Text] [Related]
18. Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes.
Gencer B; Koskinas KC; Räber L; Karagiannis A; Nanchen D; Auer R; Carballo D; Carballo S; Klingenberg R; Heg D; Matter CM; Lüscher TF; Rodondi N; Mach F; Windecker S
J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29122809
[TBL] [Abstract][Full Text] [Related]
19. [Low-density lipoprotein cholesterol target goal attainment rate and related factors in patients with acute coronary syndrome after percutaneous coronary intervention].
Zhang B; Dong X; Zhang Y; Huang R; Yin D; Zheng Z; Liu Y; Zhu H; Zhou X
Zhonghua Xin Xue Guan Bing Za Zhi; 2014 Apr; 42(4):290-4. PubMed ID: 24924454
[TBL] [Abstract][Full Text] [Related]
20. Lipid-Lowering Therapy and Low-Density Lipoprotein Cholesterol (LDL-C) Goal Achievement in High-Cardiovascular-Risk Patients in Fuzhou, China.
Wang X; He Y; Wang T; Li C; Ma Z; Zhang H; Ma H; Zhao H
J Cardiovasc Pharmacol Ther; 2020 Jul; 25(4):307-315. PubMed ID: 31918567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
